Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

GSK PLC closed 15.86% short of its 52-week high of £16.79, which the company achieved on September 9th.

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Sequoia Financial Advisors LLC grew its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK – Free Report) by 12.8% during ...

Diversified Trust Co bought a new position in shares of GSK PLC Sponsored ADR (NYSE:GSK – Free Report) during the 1st quarter ...

DelveInsight's Frontotemporal Dementia Market Insights report includes a comprehensive understanding of current treatment ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in ...

A groundbreaking NHS therapy for myeloma uses a 'Trojan horse' approach to target cancer cells, offering longer remission, ...

In a bold move to combat childhood vulnerability to preventable diseases, Save the Children's Immunisation Accelerator has ...

In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...